Sphera Funds Management LTD. bought a new stake in Urovant Sciences Ltd (NASDAQ:UROV) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 164,030 shares of the company’s stock, valued at approximately $1,968,000. Sphera Funds Management LTD. owned about 0.55% of Urovant Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently added to or reduced their stakes in UROV. FMR LLC acquired a new stake in shares of Urovant Sciences in the third quarter valued at about $14,400,000. BlackRock Inc. acquired a new position in Urovant Sciences during the third quarter worth approximately $4,574,000. Citadel Advisors LLC acquired a new position in Urovant Sciences during the third quarter worth approximately $2,209,000. Asymmetry Capital Management L.P. acquired a new position in Urovant Sciences during the third quarter worth approximately $1,902,000. Finally, Laurion Capital Management LP acquired a new position in Urovant Sciences during the third quarter worth approximately $1,200,000. 23.12% of the stock is currently owned by institutional investors and hedge funds.
In other Urovant Sciences news, major shareholder Fund V. Lp Qvt purchased 2,678,571 shares of the stock in a transaction on Monday, October 1st. The shares were purchased at an average price of $14.00 per share, with a total value of $37,499,994.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Urovant Sciences (NASDAQ:UROV) last announced its quarterly earnings results on Monday, November 12th. The company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.30). On average, equities research analysts anticipate that Urovant Sciences Ltd will post -4.04 earnings per share for the current year.
A number of equities analysts have weighed in on UROV shares. JPMorgan Chase & Co. started coverage on Urovant Sciences in a research report on Monday, October 22nd. They set an “overweight” rating and a $21.00 price target on the stock. Jefferies Financial Group started coverage on Urovant Sciences in a research report on Monday, October 22nd. They set a “buy” rating and a $19.00 price target on the stock. Finally, Cowen started coverage on Urovant Sciences in a research report on Monday, October 22nd. They set an “outperform” rating and a $25.00 price target on the stock.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Article: Relative Strength Index
Want to see what other hedge funds are holding UROV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urovant Sciences Ltd (NASDAQ:UROV).
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.